<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04076293</url>
  </required_header>
  <id_info>
    <org_study_id>HM-GLP2-101</org_study_id>
    <nct_id>NCT04076293</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912 in Healthy Korean Subjects</brief_title>
  <official_title>A First-in-Human, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912 in Healthy Korean Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A First-in-Human, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study
      to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912 in Healthy
      Korean Subjects
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event (AE) assessments, clinical laboratory tests, vital signs, 12-lead electrocardiogram (ECG), physical examinations</measure>
    <time_frame>after single subcutaneous (SC) doses for 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pharmacology</condition>
  <arm_group>
    <arm_group_label>HM15912</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM15912 or Placebo</intervention_name>
    <description>The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo). When necessary, one dosing cohort may be added or removed.
In this first-in-human (FiH) study, each cohort will be divided in 2 blocks in order to implement the sentinel dosing approach. Within each cohort, the first block will consist of 2 sentinel subjects</description>
    <arm_group_label>HM15912</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject voluntarily agrees to participate in this study and signs an IRB-approved
             informed consent prior to performing any of the Screening visit procedures.

          -  Korean males and females ≥ 19 and ≤ 60 years of age at the Screening visit

          -  Female subjects must be non-pregnant and non-lactating and either surgically sterile
             (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral
             oophorectomy), or post-menopausal for ≥ 12 months. Postmenopausal status will be
             confirmed through testing of follicle-stimulating hormone (FSH) levels ≥ 40 IU/L at
             the Screening visit for amenorrheic female subjects ≤ 60 years of age.

        Exclusion Criteria:

          -  Subject with a history or presence of clinically significant active diseases of the
             gastrointestinal, cardiovascular (including a history of arrhythmia or any clinically
             significant conduction delays in the ECG), hepatic, pulmonary, neurological, renal,
             pancreatic, immunological, dermatological, endocrine, genitourinary or hematological
             system

          -  Subject with a history or presence of skin rashes or dermatitis

          -  Subject with a history or presence of any psychiatric disorder that, in the opinion of
             the Principal Investigator, might confound the results of the study or pose additional
             risk in administering the investigational product to the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2019</study_first_posted>
  <last_update_submitted>August 30, 2019</last_update_submitted>
  <last_update_submitted_qc>August 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

